Photo from wikipedia
Severe hemophilia A is routinely managed with prophylactic replacement of factor VIII (F8), but a significant minority of patients develop anti-F8 antibodies. Extended half-life (EHL) products were developed to reduce… Click to show full abstract
Severe hemophilia A is routinely managed with prophylactic replacement of factor VIII (F8), but a significant minority of patients develop anti-F8 antibodies. Extended half-life (EHL) products were developed to reduce the frequency of infusions required. In the first prospective trial of a recombinant F8-EHL product in previously untransfused patients, Königs et al report a low 15.6% incidence of development of high-titer inhibitors.
Keywords:
first study;
life rfviiifc;
half life;
study extended;
extended half
Journal Title: Blood
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!